EVOK
Evoke Pharma, Inc. [EVOK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EVOK Stock Summary
Top 10 Correlated Stocks
EVOK
In the News
EVOK Financial details
Company Rating
-
Market Cap
4.32M
Income
-8M
Revenue
5.18M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.39
Forward P/E
-
PEG
0.48
P/S
0.7
P/B
-3.44
P/C
-
P/FCF
-0.47
Quick Ratio
3.21
Current Ratio
3.5
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.39
EPS next Y
-
EPS next Q
-
EPS this Y
-10.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
7.24%
EPS Q/Q
15.69%
-
-
-
-
SMA20
-
SMA50
66.67%
SMA100
150%
Inst Own
-
Inst Trans
-
ROA
-99%
ROE
-530%
ROC
-1.29%
Gross Margin
92%
Oper. Margin
-169%
Profit Margin
-181%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.5-2.42
52W High
-
52W Low
-
RSI
50
Rel Volume
0.45
Avg Volume
55.26K
Volume
24.9K
Perf Week
-1.92%
Perf Month
-5.02%
Perf Quarter
81.85%
Perf Half Y
33.77%
-
-
-
-
Beta
0.303
-
-
Volatility
0.05%, 0.32%
Prev Close
-1.16%
Price
5.11
Change
-0.67%
Company Profile
- Volume Average 55.26K
- Market Capitalization 4.32M
- Employee 4
- CEO Dr. Marilyn R. Carlson D.M.D., M.D., RAC.
- Headquarters Solana Beach,CA,US
- IPO Date 2013-09-25
-
Website
https://www.evokepharma.com 
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
